Switch theme
Sign up to access all valuation multiples
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
2013
407
LTM Revenue $22.8M
LTM EBITDA -$486M
$1.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
CRISPR Therapeutics has a last 12-month revenue of $22.8M and a last 12-month EBITDA of -$486M.
In the most recent fiscal year, CRISPR Therapeutics achieved revenue of $370M and an EBITDA of -$203M.
CRISPR Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See CRISPR Therapeutics valuation multiples based on analyst estimates| FY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $0.4M | $370M | $11.2M | $22.8M | XXX |
| Gross Profit | n/a | -$110M | $240M | XXX | XXX |
| Gross Margin | NaN% | -30% | 2147% | XXX | XXX |
| EBITDA | -$649M | -$203M | -$489M | -$486M | XXX |
| EBITDA Margin | -148851% | -55% | -4376% | -2127% | XXX |
| Net Profit | $378M | -$650M | -$154M | XXX | XXX |
| Net Margin | 86619% | -176% | -1376% | XXX | XXX |
| Net Debt | n/a | n/a | n/a | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 10, 2025, CRISPR Therapeutics's stock price is $40.
CRISPR Therapeutics has current market cap of $3.4B, and EV of $1.7B.
See CRISPR Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.7B | $3.4B | XXX | XXX | XXX | XXX | $-5.15 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 10, 2025, CRISPR Therapeutics has market cap of $3.4B and EV of $1.7B.
CRISPR Therapeutics's trades at 73.6x LTM EV/Revenue multiple, and -3.5x LTM EBITDA.
Analysts estimate CRISPR Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for CRISPR Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.7B | XXX | XXX | XXX |
| EV/Revenue | 150.6x | XXX | XXX | XXX |
| EV/EBITDA | -3.4x | XXX | XXX | XXX |
| P/E | -7.9x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -11.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCRISPR Therapeutics's NTM/LTM revenue growth is 598%
CRISPR Therapeutics's revenue per employee for the last fiscal year averaged $0.9M, while opex per employee averaged $1.1M for the same period.
Over next 12 months, CRISPR Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate CRISPR Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for CRISPR Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -97% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -4376% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 141% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -3779% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.9M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 21% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 105% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 125% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
CRISPR Therapeutics acquired XXX companies to date.
Last acquisition by CRISPR Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . CRISPR Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was CRISPR Therapeutics founded? | CRISPR Therapeutics was founded in 2013. |
| Where is CRISPR Therapeutics headquartered? | CRISPR Therapeutics is headquartered in United States of America. |
| How many employees does CRISPR Therapeutics have? | As of today, CRISPR Therapeutics has 407 employees. |
| Who is the CEO of CRISPR Therapeutics? | CRISPR Therapeutics's CEO is Dr. Samarth Kulkarni, PhD. |
| Is CRISPR Therapeutics publicy listed? | Yes, CRISPR Therapeutics is a public company listed on NAS. |
| What is the stock symbol of CRISPR Therapeutics? | CRISPR Therapeutics trades under CRSP ticker. |
| When did CRISPR Therapeutics go public? | CRISPR Therapeutics went public in 2016. |
| Who are competitors of CRISPR Therapeutics? | Similar companies to CRISPR Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of CRISPR Therapeutics? | CRISPR Therapeutics's current market cap is $3.4B |
| What is the current revenue of CRISPR Therapeutics? | CRISPR Therapeutics's last 12-month revenue is $22.8M. |
| What is the current EBITDA of CRISPR Therapeutics? | CRISPR Therapeutics's last 12-month EBITDA is -$486M. |
| What is the current EV/Revenue multiple of CRISPR Therapeutics? | Current revenue multiple of CRISPR Therapeutics is 73.6x. |
| What is the current EV/EBITDA multiple of CRISPR Therapeutics? | Current EBITDA multiple of CRISPR Therapeutics is -3.5x. |
| What is the current revenue growth of CRISPR Therapeutics? | CRISPR Therapeutics revenue growth between 2023 and 2024 was -97%. |
| Is CRISPR Therapeutics profitable? | Yes, CRISPR Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
